Communities in DSpace
Select a community to browse its collections.
Recent Submissions
Intellectual Property Rights and Patent Strategies in Nanotechnology-Based Pharmaceutics
(IJPHI Global Publisher Pvt. Ltd., 2026) Abdul Baseer Khan, Reetu, Ashutosh Kumar Yadav
The convergence of nanotechnology and pharmaceutical sciences has established nanotechnology-based drug delivery systems as a transformative therapeutic paradigm, while simultaneously generating unprecedented challenges for intellectual property (IP) frameworks. This chapter examines intellectual property rights (IPR) and patent strategies in nanopharmaceutics, encompassing foundational patentability criteria, nanomedicine-specific IP challenges, lifecycle management strategies, and a comparative regulatory analysis across the United States, European Union, and India. Recent advances between 2022 and 2025 in CRISPR-based nanomedicine patents, Artificial Intelligence (AI)-Al-assisted drug delivery design, personalized mRNA cancer vaccines, and next-generation lipid nanoparticle (LNP) technologies are critically evaluated. The role of Al patent tools, including PatSnap, Derwent Innovation, and Lens.org, is assessed with respect to its capabilities, limitations, and ethical concerns. Case studies encompassing Doxil, Abraxane, ONPATTRO, and mRNA-4157/V940 illustrate applied IP strategy. Ethical dimensions, including equitable access, evergreening, and technology transfer obligations, are also discussed.
Synthesis, Characterization and Anticancer Evaluations of Novel Bromobiphenyl Imidazole Chalcone
(Tashkent Institute of Chemical Technology, 2026) Jaya Gupta Mohd, Arsh Khan, Firoj Hassan
Lung cancer remains a major global health challenge and is a leading cause of cancer-related mortality, highlighting the need for novel therapeutic agents. In this study, a new bromobiphenyl-imidazole chalcone derivative, (E)-1-(4′-bromo-[1,1′-biphenyl]-4- yl)-3-(1H-imidazol-4-yl)prop-2-en-1-one, was synthesized through a Claisen–Schmidt condensation reaction and evaluated for its anticancer activity against A549 cells. The synthesized compound was obtained in good yield and subsequently subjected to biological evaluation. Cytotoxicity studies revealed that the compound exhibited significant dose-dependent inhibition of A549 cell growth with an IC50 value of 21.06μg/mL, indicating promising anticancer potential. Further mechanistic investigations demonstrated enhanced intracellular ROS generation and induction of nuclear condensation, suggesting apoptosis-mediated cell death as a possible mode of action. The observed biological activity may be attributed to the combined presence of bromobiphenyl and imidazole pharmacophores within the conjugated chalcone framework, which promotes molecular planarity, electron delocalization, and favourable interactions with cellular targets.
Comparative Investigation of TiO2, CuS and TiO2/CuS Nanomaterials Toward Efficient Solar Energy Harvesting
(Tashkent Institute of Chemical Technology, 2026) Kishor Nand, Mohd Arsh Khan, Firoj Hassan, Md. Rashid Tanveer
The synthesis, characterization and optimization of TiO2, CuS and TiO2/CuS composite nanomaterials for enhancing solar energy conversion efficiency was investigated. TiO2 nanomaterials were developed using sol-gel method. CuS nanomaterials were synthesized using hydrothermal method. Then TiO2/CuS composite nanomaterials were synthesized. These samples were analysed for their electrochemical, optical, morphological and structural properties.
X-ray diffraction and field emission scanning electron microscopy confirmed the successful formation of desired crystal phases and surface morphologies. Optical characterization revealed promising band gap energies and light absorption capabilities while electrochemical tests indicated improved photoactivity and stability.
The comparative study of TiO2, CuS and TiO2/CuS composite nanomaterials shows improved results in the composite form.
Purine Derivatives in Medicinal Chemistry: Design, Synthesis, and Application in Cancer Treatment
(Zenodo, 2026) Fiza Farooqui, Anam Saleem, Abdul Rahman Khan, Malik Nasibullah, Jamal Akhtar Ansari
Many often-used anti-cancer medications are based on heterocyclic compounds, which are fundamental to modern medicinal chemistry. Among these are purine derivatives, which are becoming well-known because of their structural resemblance to natural nucleo bases. This likeness lets them interface with biological targets promoting cancer development. Purine-based substances have shown great anticancer potential in studies on breast cancer by affecting key cellular processes including signal transduction, cell cycle control, programmed cell death, and neovascularization.
By precisely altering the purine structure at sites such C-6, N-9, and C-8, new derivatives and hybrid compounds with superior activity, selectivity, and suitable drug-like properties have been created.
These substances finally restrict the development and spread of tumor cells by targeting vital molecular targets including heat shock proteins, cyclin-dependent kinases, and enzymes engaged in purine synthesis. Several purine derivatives in particular have shown amazing efficacy against aggressive and therapy-resistant types of breast cancer including triple-negative breast cancer.
Mucuna Pruriens Chemical Constituents as Potent Male Anti- Infertility Agent
(Zenodo, 2026) Anam Saleem, Abdul Rahman Khan, Jamal Akhtar Ansari
The inability of a couple to conceive even after a year of frequent unprotected sexual activity is commonly referred to as infertility. The decline in male reproductive efficacy is increasingly attributed to molecular imbalances within the hypothalamic-pituitary-gonadal (HPG) axis and the accumulation of oxidative stressors. While synthetic interventions are available current chemical research is pivoting toward natural product scaffolds for their multi target functionality. Among these Mucuna pruriens stands out due to its high concentration of L-DOPA (L-3,4- dihydroxyphenylalanine), a non-protein amino acid that serves as a critical biochemical precursor to dopamine. This abstract examines the chemical mechanisms by which M. pruriens constituents mitigate infertility by modulating steroidogenesis and neutralizing reactive oxygen species (ROS).
The therapeutic efficacy of Mucuna pruriens is primarily driven by the structural bioavailability of its L-Dopa content. Chemically L-Dopa crosses the blood brain barrier and undergoes decarboxylation to dopamine which inhibits the release of prolactin, a peptide hormone that in excess, suppresses testosterone biosynthesis. By maintaining the chemical homeostasis of dopamine Mucuna extracts facilitate the upregulation of Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH). Furthermore, phytochemical screening of Mucuna seeds reveals a complex matrix of alkaloids polyphenols and tocopherols. These molecules possess high electron donating potential allowing them to scavenge hydroxyl and superoxide radicals within the seminal environment thereby protecting the integrity of the sperm's polyunsaturated fatty acid (PUFA) membranes from lipid peroxidation.
To ensure clinical reproducibility analytical standardization of these extracts is paramount. Advanced techniques such as Reverse-Phase High-Performance Liquid Chromatography (RP- HPLC) are utilized to quantify L-Dopa levels often using a mobile phase of dilute phosphoric acid or methanol to achieve sharp peak resolution. Additionally Liquid Chromatography-Mass Spectrometry (LC-MS/MS) is employed to map the broader "chemical fingerprint" of the seed, identifying secondary metabolites that may act synergistically with L-Dopa to enhance its stability. In conclusion, the integration of Mucuna pruriens into fertility treatments represents a sophisticated application of bio-organic chemistry where specific plant derived molecular structures are leveraged to restore systemic hormonal balance and protect cellular DNA.